The Proactive CEO Sessions in Sydney and Melbourne next week will feature pharma & biotech companies along with mining companies.
There has been good interest and there are still places available at the Sydney sessions on Monday, February 18 and at the Melbourne session the following day, February 19.
Kazia Therapeutics is developing anti-cancer drugs with its pipeline including two clinical-stage drug development candidates, which chief executive officer James Garner will outline to investors.
Its lead candidate is GDC-0084, which entered a phase II clinical trial in March 2018, and Kazia expects initial data early this year followed by other data read-outs.
GDC-0084 is being developed for glioblastoma multiforme, the most common and most aggressive form of primary brain cancer.
Chemotherapy treatment temozolomide is only effective in one-third of patients and, furthermore, the median survival rate is 12 to 15 months from diagnosis, meaning there is a demand for superior treatments.
Peninsula Energy is transitioning towards a low pH uranium operation at its Lance Projects in the US state of Wyoming and managing director Wayne Heili will outline its progress.
The shift towards acid leaching operations, or low pH techniques, is expected to lower operating costs and enhance recoveries.
As part of this transition process, a field demonstration has been taking place while regulatory and permitting work advances.
AdAlta is focused on developing treatments for fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), which CEO and director Sam Cobb will speak about.
The biotechnology company aims to develop and commercialise its i-body technology platform that has generated a pipeline of i-bodies, with an initial focus on treating fibrotic diseases.
IPF is an irreversible, unpredictable and incurable disease with at least 1,500 Australians diagnosed each year. Only 20% of patients diagnosed survive five years.
Argonaut Resources is drilling at the Lake Torrens project in South Australia, targeting a copper-gold anomaly with a footprint larger than the nearby Olympic Dam iron oxide-copper-gold project (IOCG) of BHP Group Ltd (ASX:BHP).
CEO Lindsay Owler will update investors on this work and the company’s plans.
Stage one of this program comprises 8-10 drill holes to depths of 700-1,500 metres.
IOCG targets have been identified from gravity modelling and geological interpretation.
At the Sydney event, Theta Gold Mines’ chairman Bill Guy will outline the company’s strategy focused on gold in South Africa.
The company is focused on the historical TGME gold mining area around the town of Pilgrims Rest northeast of Johannesburg and has a resource and reserve statement imminent, which is expected to add to the 5.8 million-ounce gold resource.
It will also form part of a feasibility study for the Theta Hill project, which is intended to be the first producing mine in the broader TGME project.
The fully-funded study is due for completion later this quarter.
Anatara Lifesciences is focused on its new business strategy in human health, and in particular the development and partnering of its GaRP dietary supplement.
Chief executive officer Steven Lydeamore will explain how the company is well advanced in proof of concept studies for product candidate GaRP, which is an evidence-based dietary supplement aimed at restoring and maintaining gut health.
With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).
Register for the CEO Sessions today to find out more.